Atlas Trials

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Clinical trial NCT02978625 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02978625
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Anaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-PositiveApocrine CarcinomaCarcinoma Arising From CylindromaCarcinoma Arising From SpiradenomaDigital Papillary AdenocarcinomaEndocrine Mucin-Producing Sweat Gland CarcinomaExtramammary Paget DiseaseExtraocular Sebaceous CarcinomaHidradenocarcinomaMalignant Sweat Gland NeoplasmMerkel Cell Carcinoma
Start date
2017-09-27
Primary completion
2027-09-01
Enrollment
68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.